News
//76Results
-
Corporate News
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance
Frankfurt am Main /
Frankfurt am Main, July 16, 2026 – The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market…
Read more -
Corporate News
Merz Group Expands Management Board: Dr. Almuth Steinkühler Appointed New Chief Financial Officer (CFO)
Frankfurt am Main /
Frankfurt am Main, October 28 – The Merz Group, an international, diversified, family-owned healthcare company, is positioning itself for the future by expanding its Executive Board: Effective November 1, Dr.…
Read more -
Corporate
Generational transition of Shareholder Leadership in the family owned Merz Group
Frankfurt am Main /
Carefully planned leadership transition ensures continuity and renewal. Frankfurt am Main / 06.01.2025 / Merz has been under the ownership of its founding family since its establishment in 1908. Merz…
Read more -
Corporate
Merz enters Asset Purchase Agreement with a US-based biotech company
Frankfurt am Main /
Second investment in a NASDAQ company in just over ten years. Frankfurt am Main, Germany / April 1, 2024 / Merz Therapeutics, a business of Frankfurt-based Merz Group, has entered…
Read more -
Corporate
New CEO for Merz Therapeutics: Stefan König
Frankfurt am Main /
Mexico City, London, and now Frankfurt am Main, Germany: Experienced Pharma manager appointed to lead Merz Therapeutics As of immediately, Stefan König will be responsible for Merz Therapeutics GmbH as…
Read more -
Corporate News
New CEO for Merz Consumer Care: Xenia Barth
Frankfurt am Main /
As an experienced manager for consumer beauty care marketing and sales, Xenia Barth is taking over the management of Merz Consumer Care. From now on, Xenia Barth will be responsible…
Read more -
Neurotoxin
XEOMIN® (incobotulinumtoxinA) Receives European Approval for the Treatment of Chronic Sialorrhea in Children
Frankfurt, Germany /
First and only botulinum neurotoxin approved for this indication in Europe Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been…
Read more -
Corporate
Merz and Israeli start-up Vensica launch partnership for needleless treatment of overactive bladder
Frankfurt, Germany /
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced today that they…
Read more -
Neurotoxin
Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A
Frankfurt, Germany /
Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly…
Read more -
Corporate
Merz Healthcare Breaks Even Despite COVID-19 Pandemic in Fiscal Year 2019/20
Frankfurt, Germany /
Net consolidated operating profit of the Frankfurt family business amounts to EUR 38.8 million Partnership with Gwyneth Paltrow and investment in start-up Brooklyn Soap Company Investments in the new organizational structure pay…
Read more